UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

A multicenter, open-label, single-arm phase I trial of neoadjuvant nivolumab monotherapy for resectable gastric cancer

Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association, 2022-05, Vol.25 (3), p.619-628

2022

Volltextzugriff (PDF)

Three-year outcomes of a randomized phase III trial comparing adjuvant chemotherapy with S-1 plus docetaxel versus S-1 alone in stage III gastric cancer: JACCRO GC-07

Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association, 2022, Vol.25 (1), p.188-196

2022

Volltextzugriff (PDF)

Phase 2 study of irinotecan plus cetuximab rechallenge as third-line treatment in KRAS wild-type metastatic colorectal cancer: JACCRO CC-08

British journal of cancer, 2020-11, Vol.123 (10), p.1490-1495

2020

Volltextzugriff (PDF)

Correction: Addition of docetaxel to S-1 results in significantly superior 5-year survival outcomes in Stage III gastric cancer: a final report of the JACCRO GC-07 study

Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association, 2024-09, Vol.27 (5), p.1157-1157

2024

Volltextzugriff (PDF)

Addition of docetaxel to S-1 results in significantly superior 5-year survival outcomes in Stage III gastric cancer: a final report of the JACCRO GC-07 study

Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association, 2023-11, Vol.26 (6), p.1063-1068

2023

Volltextzugriff (PDF)

Small Bowel Bleeding Caused by a Small Bowel Lipoma in a Patient with Hemodialysis

Case reports in gastroenterology, 2024-01, Vol.18 (1), p.373-378

2024

Volltextzugriff (PDF)

Recent advances in chemotherapy for advanced gastric cancer in Japan

Surgery today (Tokyo, Japan), 2010-04, Vol.40 (4), p.295-300

2010

Volltextzugriff (PDF)

Clinical verification of circulating tumor RNA (ctRNA) as novel pretreatment predictor and tool for quantitative monitoring of treatment response in metastatic colorectal cancer (mCRC): A biomarker study of the DEEPER trial

Journal of clinical oncology, 2019-05, Vol.37 (15_suppl), p.TPS3621-TPS3621

2019

Volltextzugriff (PDF)

Impact of nutritional status in the era of FOLFOX/FIRI-based chemotherapy

World journal of surgical oncology, 2017-08, Vol.15 (1), p.162-162, Article 162

2017

Volltextzugriff (PDF)

Tumor Sidedness and Enriched Gene Groups for Efficacy of First-line Cetuximab Treatment in Metastatic Colorectal Cancer

Molecular cancer therapeutics, 2018-12, Vol.17 (12), p.2788-2795

2018

Volltextzugriff (PDF)

Human epidermal growth factor 2 overexpressed alpha-fetoprotein-producing-gastric cancer

Discover. Oncology, 2023-06, Vol.14 (1), p.111-111, Article 111

2023

Volltextzugriff (PDF)

Differing deregulation of HER2 in primary gastric cancer and synchronous related metastatic lymph nodes

Diagnostic pathology, 2013-11, Vol.8 (1), p.191-191, Article 191

2013

Volltextzugriff (PDF)

Successful Management of the Cervicothoracic Esophagus Reconstruction by Expanded Skin Flap

The Annals of thoracic surgery, 2014-12, Vol.98 (6), p.2211-2213

2014

Volltextzugriff (PDF)

Addition of Docetaxel to Oral Fluoropyrimidine Improves Efficacy in Patients With Stage III Gastric Cancer: Interim Analysis of JACCRO GC-07, a Randomized Controlled Trial

Journal of clinical oncology, 2019-05, Vol.37 (15), p.1296-1304

2019

Volltextzugriff (PDF)

CEA Response and Depth of Response (DpR) to Predict Clinical Outcomes of First-Line Cetuximab Treatment for Metastatic Colorectal Cancer

Targeted oncology, 2017-12, Vol.12 (6), p.787-794

2017

Volltextzugriff (PDF)

A Phase II Study of Cetuximab and MFOLFOX6 in MCRC Including Prospective Early Tumor Shrinkage Analysis (JACCRO-CC05)

Annals of oncology, 2013-06, Vol.24, p.iv94-iv94

2013

Volltextzugriff (PDF)

Post-recurrent survival of a phase III trial comparing adjuvant chemotherapy with docetaxel plus S-1 versus S-1 alone in stage III gastric cancer: A post-hoc analysis of the START-2 trial (JACCRO GC-07)

Journal of clinical oncology, 2023-02, Vol.41 (4_suppl), p.371-371

2023

Volltextzugriff (PDF)

A complete response to S-1 plus cis-diamminedichloroplatinum in advanced-stage esophageal and gastric adenocarcinoma: a case report

World journal of surgical oncology, 2012-07, Vol.10 (1), p.133-133, Article 133

2012

Volltextzugriff (PDF)

Complete Remission of Unresectable Rectal CancerFollowing FOLFOXIRI and Cetuximab Treatment

Nichidai igaku zasshi, 2021-10, Vol.80 (5), p.259-262

2021

Volltextzugriff (PDF)

Genome-wide DNA methylation status to predict the efficacy of modified (m)-FOLFOXIRI plus cetuximab as initial treatment for RAS wild-type metastatic colorectal cancer: A biomarker study of the DEEPER trial (JACCRO CC-13AR)

Journal of clinical oncology, 2024-01, Vol.42 (3_suppl), p.152-152

2024

Volltextzugriff (PDF)

PS4-3 Survival analysis of m-FOLFOXIRI plus cetuximab vs. bevacizumab in RAS wild-type mCRC: The DEEPER trial (JACCRO CC-13)

Annals of oncology, 2023-11, Vol.34, p.S1381-S1381

2023

Volltextzugriff (PDF)

Five-year overall survival with S-1 plus docetaxel as adjuvant treatment in curatively resected pStage III gastric cancer in JACCRO GC-07

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.4065-4065

2023

Volltextzugriff (PDF)

Evaluation of serum CEA and CA19-9 levels as prognostic factors in patients with gastric cancer

Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association, 2000-12, Vol.3 (4), p.177-186

2000

Volltextzugriff (PDF)

Modified (m)-FOLFOXIRI plus cetuximab versus m-FOLFOXIRI plus bevacizumab as initial treatment of patients with unresectable RAS and BRAF wild-type metastatic colorectal cancer: Survival analysis of the phase II randomized DEEPER trial by JACCRO

Journal of clinical oncology, 2023-02, Vol.41 (4_suppl), p.120-120

2023

Volltextzugriff (PDF)

Neoadjuvant nivolumab monotherapy in patients with resectable gastric cancer: Preliminary results from a multicenter study

Journal of clinical oncology, 2021-05, Vol.39 (15_suppl), p.4026-4026

2021

Volltextzugriff (PDF)

1 – 25 von 119

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(103)
Mit Volltextzugriff
(89)

Publikationsform

Artikel
(117)
Berichte
(2)

Sprache

Englisch
(104)
Japanisch
(21)

Erscheinungsjahr

n.n

Thema

Humans
(53)
Life Sciences & Biomedicine
(49)
Science & Technology
(49)
Male
(40)
Aged
(37)
Female
(34)
Middle Aged
(33)
Oncology
(32)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(28)
Adult
(22)
Stomach Neoplasms - Drug Therapy
(22)
Gastric Cancer
(21)
Treatment Outcome
(19)
Chemotherapy
(18)
Stomach Neoplasms - Pathology
(18)
Surgery
(18)
Aged, 80 And Over
(17)
Biological And Medical Sciences
(17)
Medical Sciences
(17)
Prognosis
(17)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

A multicenter, open-label, single-arm phase I trial of neoadjuvant nivolumab monotherapy for resectable gastric cancer

Three-year outcomes of a randomized phase III trial comparing adjuvant chemotherapy with S-1 plus docetaxel versus S-1 alone in stage III gastric cancer: JACCRO GC-07

Phase 2 study of irinotecan plus cetuximab rechallenge as third-line treatment in KRAS wild-type metastatic colorectal cancer: JACCRO CC-08

Correction: Addition of docetaxel to S-1 results in significantly superior 5-year survival outcomes in Stage III gastric cancer: a final report of the JACCRO GC-07 study

Addition of docetaxel to S-1 results in significantly superior 5-year survival outcomes in Stage III gastric cancer: a final report of the JACCRO GC-07 study

Small Bowel Bleeding Caused by a Small Bowel Lipoma in a Patient with Hemodialysis

Recent advances in chemotherapy for advanced gastric cancer in Japan

Clinical verification of circulating tumor RNA (ctRNA) as novel pretreatment predictor and tool for quantitative monitoring of treatment response in metastatic colorectal cancer (mCRC): A biomarker study of the DEEPER trial

Impact of nutritional status in the era of FOLFOX/FIRI-based chemotherapy

Tumor Sidedness and Enriched Gene Groups for Efficacy of First-line Cetuximab Treatment in Metastatic Colorectal Cancer

Human epidermal growth factor 2 overexpressed alpha-fetoprotein-producing-gastric cancer

Differing deregulation of HER2 in primary gastric cancer and synchronous related metastatic lymph nodes

Successful Management of the Cervicothoracic Esophagus Reconstruction by Expanded Skin Flap

Addition of Docetaxel to Oral Fluoropyrimidine Improves Efficacy in Patients With Stage III Gastric Cancer: Interim Analysis of JACCRO GC-07, a Randomized Controlled Trial

CEA Response and Depth of Response (DpR) to Predict Clinical Outcomes of First-Line Cetuximab Treatment for Metastatic Colorectal Cancer

A Phase II Study of Cetuximab and MFOLFOX6 in MCRC Including Prospective Early Tumor Shrinkage Analysis (JACCRO-CC05)

Post-recurrent survival of a phase III trial comparing adjuvant chemotherapy with docetaxel plus S-1 versus S-1 alone in stage III gastric cancer: A post-hoc analysis of the START-2 trial (JACCRO GC-07)

A complete response to S-1 plus cis-diamminedichloroplatinum in advanced-stage esophageal and gastric adenocarcinoma: a case report

Complete Remission of Unresectable Rectal CancerFollowing FOLFOXIRI and Cetuximab Treatment

Genome-wide DNA methylation status to predict the efficacy of modified (m)-FOLFOXIRI plus cetuximab as initial treatment for RAS wild-type metastatic colorectal cancer: A biomarker study of the DEEPER trial (JACCRO CC-13AR)

PS4-3 Survival analysis of m-FOLFOXIRI plus cetuximab vs. bevacizumab in RAS wild-type mCRC: The DEEPER trial (JACCRO CC-13)

Five-year overall survival with S-1 plus docetaxel as adjuvant treatment in curatively resected pStage III gastric cancer in JACCRO GC-07

Evaluation of serum CEA and CA19-9 levels as prognostic factors in patients with gastric cancer

Modified (m)-FOLFOXIRI plus cetuximab versus m-FOLFOXIRI plus bevacizumab as initial treatment of patients with unresectable RAS and BRAF wild-type metastatic colorectal cancer: Survival analysis of the phase II randomized DEEPER trial by JACCRO

Neoadjuvant nivolumab monotherapy in patients with resectable gastric cancer: Preliminary results from a multicenter study

Suchergebnisse filtern